FDA OKs First Digital Therapeutic App for Depression: Otsuka

April 4, 2024
The US FDA has cleared “Rejoyn,” developed by Otsuka Pharmaceutical and Click Therapeutics, as the first prescription digital therapeutic authorized in the country for the adjunctive treatment of major depressive disorder (MDD) symptoms. The green light was granted on March...read more